clinical trial · NCT06434961
The Trial of SHR6508 in Secondary Hyperparathyroidism
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase3·completed·n = 498
Secondary HyperparathyroidismSHR6508 plus oral placebo tabletsCinacalcet plus intravenous placebo
brief summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
started
Jun 14, 2024
primary completion
Sep 29, 2025
completion
Nov 11, 2025
last updated
Dec 12, 2025
official title
A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol